Poster Abstract Session:
144. Novel Agents
Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Investigative ID


Presentations:
Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
Lindsey Cass, PhD; Amanda Davis, PhD; Alison Murray, MBBCh, FRCPath; Kathy Woodward, RNG, PgDip; Kazuhiro Ito, PhD; Pete Strong, PhD; Garth Rapeport, MD, PhD
Posters
  • 1335_IDWPOSTER V2 Logo.pdf (660.7 kB)
  • A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Versus Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections
    David Huang, MD, PhD, FIDSA, FACP; G. Ralph Corey, MD; Thomas L. Holland, MD; Thomas P. Lodise Jr., PharmD, PhD; William O'Rirodan, MD; Mark Wilcox, MD; Thomas M. File Jr., MD; Matthew Dryden, MD, FRCPath, FRCPS; Antoni Torres, MD, PhD, FERS; Barbara Balser, DVM; Eve Desplats, BS
    Posters
  • IDWeek_Poster 1338.pdf (974.8 kB)
  • Results for the supplemental microbiological modified intent-to-treat (SmMITT) population of the RESTORE-IMI 1 trial of imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients (pts) with imipenem-nonsusceptible (NS) bacterial infections
    Keith Kaye, MD, MPH; Thomas File, MD; Helen W. Boucher, MD, FIDSA; Michelle Brown, RN; Angela Aggrey, PhD; Ireen Khan, MD; Hee-Koung Joeng, PhD; Robert Tipping, MS; Jiejun Du, PhD; Katherine Young, MS; Joan Butterton, MD; Nicholas A. Kartsonis, MD; Amanda Paschke, MD, MSCE
    Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
    Michael Trang, Pharm.D.; Justin C. Bader, Pharm.D., MBA; Eric A. Ople, BSc; William G. Kramer, Ph.D.; Michael R. Hodges, MBBS, BSc; Sujata M. Bhavnani, Pharm.D., M.S.; Christopher M. Rubino, Pharm.D.
    Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model
    Shinya Shano, MS; Keita Fukao, MS; Takeshi Noshi, MS; Kenji Sato, MS; Masashi Sakuramoto, MS; Kaoru Baba, AS; Takao Shishido, PhD; Akira Naito, Ph. D.
    The Tetrazole VT-1598 is Efficacious in a Murine Model of Invasive Aspergillosis with a PK/PD Expected of a Mold-Active CYP51 Inhibitor
    Edward P Garvey, PhD; Andrew Sharp, BSc; Peter Warn, PhD; Christopher M Yates, MS; Robert J Schotzinger, MD/PhD
    Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
    Fredrick M. Abrahamian, DO; George Sakoulas, MD; Evan Tzanis, BA; Amy Manley, BS; Judith N. Steenbergen, PhD; Anita Das, PhD; Paul Eckburg, MD; Paul McGovern, MD
    In vitro activity of plazomicin, a next-generation aminoglycoside, against carbapenemase-producing Klebsiella pneumoniae
    Michael R. Jacobs, MD PhD; Caryn E. Good, MA/MPH; Ayman M. Abdelhamed, MD PhD; Daniel D. Rhoads, MD; Kristine M. Hujer, BS; Andrea M. Hujer, BS; Susan D. Rudin, BS; T. Nicholas Domitrovic, MS; Lynn Connolly, MD, PhD; Kevin M. Krause, MBA; Sandra S. Richter, MD; David Van Duin, MD, PhD; Barry N. Kreiswirth, PhD; Robert A. Bonomo, MD
    Posters
  • 1348_IDWPOSTER_PLAZOMICIN.pdf (829.1 kB)
  • Global Surveillance of Cefiderocol against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
    Masakatsu Tsuji, Ph.D; Meredith Hackel, PhD, MPH; Roger Echols, MD, FIDSA; Yoshinori Yamano, Ph.D; Dan Sahm, PhD
    Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
    Mitsutaka Kitano, Ph.D.; Takanobu Matsuzaki, MS; Ryoko Oka, BS; Kaoru Baba, AS; Takahiro Noda, AS; Yuki Yoshida, MS; Kenji Sato, MS; Ryu Yoshida, Ph. D.; Akihiko Sato, Ph. D.; Hiroshi Kamimori, Ph. D.; Takao Shishido, PhD; Akira Naito, Ph. D.
    Posters
  • IDWeek_ferret.pdf (792.7 kB)
  • In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases
    Michael R. Jacobs, MD PhD; Ayman M. Abdelhamed, MD PhD; Caryn E. Good, MA/MPH; Daniel D. Rhoads, MD; Kristine M. Hujer, BS; Andrea M. Hujer, BS; T. Nicholas Domitrovic, MS; Susan D. Rudin, BS; Sandra S. Richter, MD; David Van Duin, MD, PhD; Barry N. Kreiswirth, PhD; Robert A. Bonomo, MD
    Global Activity of Imipenem-Relebactam and Comparators against Clinical Gram-Negative Pathogens – SMART 2017
    Sibylle Lob, Ph.D; Krystyna Kazmierczak, Ph.D; Daryl Hoban, Ph.D; Meredith Hackel, Ph.D; Katherine Young, MS; Mary Motyl, PhD; Dan Sahm, PhD
    Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid
    Evan Tzanis, BA; Surya Chitra, PhD, MBA; Marla Curran, DrPH; Paul McGovern, MD; Jordan Hinahara, BA; Thomas Goss, Pharm. D.
    A combination of itraconazole and amiodarone is highly effective against Trypanosoma cruzi infection of human stem cell derived cardiomyocytes
    Gabriele Sass, PhD; Roy Madigan, DVM; Adriana Bozzi, PhD; Nazish Sayed, MD, PhD; Joseph Wu, MD; David Stevens, MD
    Activity of Meropenem/Nacubactam Combination against Gram-negative Clinical Isolates: ROSCO Global Surveillance 2017
    Rusudan Okujava, PhD; Fernando Garcia-Alcalde, PhD; Andreas Haldimann, PhD; Claudia Zampaloni, PhD; Ian Morrissey, PhD; Sophie Magnet, PhD; Nimmi Kothari, MSc; Ian Harding, PhD; Kenneth Bradley, PhD
    Posters
  • Poster 1359_IDweek2018.pdf (398.6 kB)
  • A Novel Intravesical Antimicrobial for CAUTIs
    Marnie Peterson, PharmD, PhD; Samuel Kilgore, BS; Patrick Schlievert, PhD
    Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection.
    Sailaja Puttagunta, MD; Steven Aronin, MD; Michael Huband, BS; Robert K. Flamm, PhD; Michael Dunne, MD
    Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials
    Rodrigo E. Mendes, Ph.D.; Mariana Castanheira, PhD; Eliana S Armstrong, PhD; Judith N. Steenbergen, PhD; Robert K. Flamm, PhD
    In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas maltophilia Clinical Isolates
    Akinobu Ito, Ph.D; Merime Ota, Bachelor; Rio Nakamura, Bachelor; Masakatsu Tsuji, Ph.D; Takafumi Sato, Ph.D; Yoshinori Yamano, Ph.D
    Clinical Cure in Secondary Efficacy Populations in Patients with Complicated Urinary Tract Infection Treated with ZTI-01 (fosfomycin for injection): Findings from the ZEUS Trial
    Keith Kaye, MD, MPH; Louis B. Rice, MD, FIDSA; Viktor Stus, MD, PhD; Olexsiy Sagan, MD; Elena Fedosiuk, MD; Anita Das, PhD; David Skarinksy, BS; Paul B. Eckburg, M.D.; Kristina Manvelian, MS; Evelyn J. Ellis-Grosse, PhD
    Posters
  • IDWeek CONTEPO_1367.pdf (477.3 kB)
  • Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.
    Denis Daigle, Ph.D.; Jodie Hamrick, B.Sc.; Cassandra Chatwin, B.Sc.; Natalia Kurepina, Ph.D.; Barry N. Kreiswirth, PhD; Ryan K. Shields, PharmD; Antonio Oliver, PhD; Cornelius J. Clancy, M.D.; Minh-Hong Nguyen, MD; Daniel Pevear, Ph.D.; Luigi Xerri, Ph.D.
    Posters
  • 1370_IDWPOSTER_v2.jpg (3.1 MB)
  • Activity of Ceftriaxone-Sulbactam-EDTA Against Multi-Drug Resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India  
    Ruchi Girotra, DNB (Microbiology); Anurag Pyasi, PhD; Manu Chaudhary, PhD; N. S. Patil, MD (Microbiology); Mohd Amin Mir, MS, MSc, PGDPM; Saransh Chaudhary, BSc (Hons); Pankaj Mandale, MBBS, MPH
    Posters
  • 1373_SURVEILLANCE_CSE 1.pdf (4.3 MB)
  • Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
    Steven Opal, MD; Thomas M. File Jr., MD; Tom Van Der Poll, MD, PhD; Paul McGovern, MD; Evan Tzanis, BA; Surya Chitra, PhD, MBA
    Posters
  • IDWeek Poster 1374.pdf (181.6 kB)
  • In vitro Activity of Cefiderocol and Comparator Agents against Gram-negative Isolates from Cancer Patients
    Kenneth V.I. Rolston, MD; Bahgat Gerges, PhD; Issam Raad, MD; Samuel L. Aitken, PharmD; Ruth Reitzel, PhD; Randall Prince, PharmD, FIDSA
    Antifungal activity of cerium nitrate against fungal isolates associated with combat-related injuries including burns
    Heather Pomerantz, MD; Miriam Beckius, MPH; Dana Blyth, MD; Kevin S. Akers, MD, FIDSA; David R. Tribble, MD, DrPH, FIDSA; Katrin Mende, PhD
    Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
    Rodrigo E. Mendes, Ph.D.; Mariana Castanheira, PhD; Eliana S Armstrong, PhD; Judith N. Steenbergen, PhD; Robert K. Flamm, PhD
    Evaluation of the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae, including isolates resistant to ceftazidime-avibactam
    William R. Wilson, PharmD; Ellen Kline, MS; Chelsea Jones, BA; Kristin Morder, BA; Cornelius J. Clancy, M.D.; M. Hong Nguyen, MD; Ryan K. Shields, PharmD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.